Artificial Intelligence
Drug Discovery Services Market Size Worth USD 47,868.59 Million by 2030 at 13.92% CAGR – Report by Market Research Future (MRFR)
New York, USA, Jan. 11, 2023 (GLOBE NEWSWIRE) — Drug Discovery Services Market Overview
According to a Comprehensive Research Report by Market Research Future (MRFR), “Drug Discovery Services Market Information By Drug Type, Types of Services, Therapeutic Area, Technology, End User and Region – Forecast till 2030“, the market size is projected to be worth USD 47,868.59 million by 2030, registering a CAGR of 13.92% during the forecast period (2022 – 2030)
Market Synopsis
Designing a new drug is the process of drug discovery. Molecular manipulation, random screening, molecular designing, drug metabolites, and serendipity are the most often used techniques for drug discovery. The services available minimize the costs and durations associated with drug discovery. The process of drug discovery is used in pharmacology, biotechnology, and healthcare to create and find new treatments. In forensics, disaster victim identification, paternity testing, and anthropology, drug discovery services are frequently employed, and DNA analysis is critical in these fields. Increased R&D spending, big pharmaceutical companies’ tendency to outsource to avoid obstacles, and a rise in demand for analytical testing & clinical study services are the main drivers propelling the expansion of this market.
The recognition of aspirants, manufacture, portrayal, selection and tests for therapeutic utility are all included in this procedure. The global market for drug discovery services is expanding as a result of several additional factors, including an increase in chronic disease awareness, an expansion of the patient base, an increase in unmet medical needs, the patent expiry of blockbuster drugs, improved regulatory frameworks for drug discovery, and an increase in funding and reimbursement. A molecule will start the drug development process culminating in clinical trials once it has demonstrated its utility in these evaluations. The core of drug discovery services consists of lead compound identification, lead optimization, drug target identification, drug discovery selection, and drug design, depending on the fragment. Increased outsourcing of lead identification services is made possible by the growing demand for professional workers who combine knowledge of analytical chemistry, metabolism, and computer software with the expensive expense of integrating the most cutting-edge computing technologies.
Get Free Sample PDF Brochure @ https://www.marketresearchfuture.com/sample_request/5870
Report Scope:
| Report Attribute | Details |
| Market Size in 2030 | USD 47,868.59 Million |
| CAGR | 13.92% |
| Base Year | 2021 |
| Forecast Period | 2022-2030 |
| Historical Data | 2020 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | By Drug Type, Types of Services, Therapeutic Area, Technology and End-User |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Market Drivers | Increasing research & development expenditure |
| Rising drug development outsourcing |
Drug Discovery Services Market Competitive Landscape:
The pivotal contenders in the drug discovery services market are:
- Thermo Fisher Scientific INC. (US)
- Sygnature Discovery (UK)
- Symeres (Netherlands)
- Eurofins Scientific (Europe)
- IQVIA (US)
- Evotec (Germany)
- WuXi AppTec Co., Ltd. (China)
- Laboratory Corporation of America Holdings (US)
- Aragen Life Sciences Pvt. Ltd (India)
- Piramal Pharma Solutions (India)
- Curia Global, Inc. (US)
- Charles River Laboratories (US)
- Selvita (Poland)
- NuChem Sciences Inc (Canada)
- Paraza Pharma, Inc. (Canada)
Drug Discovery Services Market Dynamics:
Market Drivers:
The market for drug discovery services is seeing new revenue streams driven by increased pharmaceutical and biopharmaceutical R&D investment, growing preference for contracted analytical testing services, and initiatives for rare illness and orphan medication development. The market for drug discovery services is expanding significantly, mostly due to increased demand and supply for pharmaceuticals. Additionally, factors including technological development, a rise in the use of discovery methods, rising generic medicine demand, and an increase in the number of patent expirations all contribute to the market’s expansion on a global scale. The expansion of R&D activities, the growth of the healthcare industry, the rise in the need for generic medications, the rise in the population of the elderly, and technical improvements in the industry are other factors fueling the market’s expansion.
Biologics, biosimilars, and large-molecule drugs are expanding their market share even though small-molecule pharmaceuticals still account for most of the global pharmaceutical market. This is primarily because new biologic-based treatments are being developed and because current biologics are earning more money. Additionally, biologics and biosimilars at each level require more sophisticated testing services than small molecules. Therefore, the market for drug discovery services is projected to develop over the next years due to the rising demand for outsourcing these tasks to CROs.
Browse In-depth Market Research Report (110 Pages) on Drug Discovery Services: https://www.marketresearchfuture.com/reports/drug-discovery-services-market-5870
Market Restraints:
On the other hand, strict regulations governing medication research and animal testing are anticipated to restrain market expansion partially. Due to a lack of qualified staff, drug discovery services face a dilemma. However, the FDA’s strict rules, the need for a significant capital investment with low profit margins, and the comparably subpar healthcare systems in middle- and low-income nations restrain the market’s expansion for drug discovery services.
COVID 19 Analysis
Drug discovery and development are being done to find new medications and develop existing ones that can cure COVID-19 symptoms and prevent viral replication. Future drug discovery technologies, including bioinformatics, high throughput, and medicinal chemistry, are increasingly being applied in the drug discovery services market to identify drug candidates better. Companies have intensified anti-infective medicine R&D after seeing the need in the future. The market expansion is expected to gain from this.
Buy Now: https://www.marketresearchfuture.com/checkout?currency=one_user-USD&report_id=5870
Drug Discovery Services Market Segmentation
By end user, the market includes pharmaceutical & biotechnology companies, research & academics.
By drug type, the market includes small molecule drugs and biologics drugs. By therapeutic area, the market includes oncology, cardiovascular diseases, respiratory diseases, and diabetes.
By types of services, the market includes drug metabolism and pharmacokinetics (DMPK) services, pharmaceutical services, medicinal chemistry, biological services, and medication.
By technology, the market includes high throughput screening, biochips, pharmacogenomics and pharmacogenetics, and metabolomics.
Share your Queries @ https://www.marketresearchfuture.com/enquiry/5870
Drug Discovery Services Market Regional Insights
Regarding the pharmaceutical sector spending on research and development, North America leads the world. The region is also home to the largest markets for bulk pharmaceuticals and dosage forms. The region’s drug discovery services market operates as a free market with transparent trading practices and restrictions on anti-competitive behavior. Increased investments in drug discovery R&D, significant firms with established research infrastructure, and technical improvements can all be linked to the regional market’s growth. During the forecast period, Asia is anticipated to have the fastest CAGR. Due to the availability of trained labor, cheaper costs, a supportive regulatory framework, and high-quality data, the area quickly becomes a center for outsourcing drug discovery activities. The second-largest market in the world, Japan, is anticipated to offer CROs a significant opportunity to drive the industry.
Discover more research Reports on Healthcare Industry by Market Research Future:
Drug Discovery Informatics Market Share, Trends And Size Analysis By Product (Discovery Informatics, Development Informatics), Mode (In-House Informatics), Service (Clinical Trial Data Management, Molecular Modeling), & End User—Forecast Till 2030
Artificial Intelligence in Drug Discovery Market Research Report, By Product Type (Software, Services), Molecule Type (Large Molecule, Small Molecule), Technology (Machine Learning, Deep Learning and others), Indication (Immune-Oncology, Neurodegenerative Diseases, Cardiovascular Diseases, Metabolic Diseases and others), Application (Target Identification, Candidate Screening, De novo Drug Designing, Drug Optimization and Repurposing and Preclinical Testing) – Forecast till 2030
Contract Research Organization (CRO) Market Research Report, By Segment (Drug Discovery, Clinical Development), By Clinical Trial Phase (Preclinical Trials, Phase I, Phase II, Phase III), By End Users (Pharmaceutical Companies) – Forecast till 2030
About Market Research Future:
Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.
Artificial Intelligence
DCI Indonesia Awarded by Frost & Sullivan for World-class Operational Excellence, Enabling Customers to Grow and Thrive, and Securing a Market-leading Position
DCI Indonesia’s expansions, backed by its focus on industry best practices, sustainability, and alignment with customer trends, reinforce its strategic advantage.
SAN ANTONIO, July 3, 2024 /PRNewswire/ — Frost & Sullivan recently analyzed the data center services industry and, based on its findings, recognized DCI Indonesia with the 2024 Company of the Year Award for a fifth consecutive time. The company is the leading data center services provider in Indonesia, offering best-in-class, scalable, and reliable data center colocation services and solutions. Its portfolio includes colocation, bare metal, physical security, data center connectivity, cooling, and power management to improve operational excellence, enabling customers to grow and thrive. The company supports a diverse client base, including global cloud service providers, major e-commerce and social media companies, telecommunication service providers, financial services industries, and enterprises from various verticals.
DCI currently offers 83 megawatts (MW) of power capacity across Cibitung, Karawang and Jakarta, where clients can directly connect with 4 of the world’s biggest cloud platforms. The DCI Indonesia Platform maximizes headcount efficiency in data center operations and provides customers with improved power usage effectiveness and energy cost stability. Furthermore, DCI offers Renewable Energy Certificates (RECs), as well as green energy from biomass and solar farms as they lead the sustainability front in the industry.
Nishchal Khorana, global vice president and program leader for ICT at Frost & Sullivan, observed, “DCI Indonesia reinforces its strategic advantage with a compelling value proposition of tailored solutions and carrier-neutral facilities–the highest Tier IV service quality, best practice AI-driven operations, and competitive pricing. The company is an established data center operator with a 100% power uptime track record for over a decade, trusted by hundreds of clients in its portfolio to house their most critical IT infrastructure.”
DCI Indonesia is a member of a global business community that meets high social and environmental impact standards. With its sterling reputation and a client-centric approach at its core, it establishes ongoing trust with customers and fosters long-lasting relationships that extend throughout the data center service lifecycle. The company generates over USD $90 million in revenue, achieving at least 25% year-on-year growth with an impressive net profit margin. Its stellar growth momentum and trajectory are a testament to its service leadership, its ability to earn client trust and loyalty, and its capability to capture market share. The company is well-positioned to drive the data center service space into its next growth phase, capturing market share and sustaining its strategic leadership in the coming years.
“DCI Indonesia pioneers the highest standards, enabling its scalable, reliable, and carrier-neutral capabilities and services to meet clients’ ever-evolving digital infrastructure needs. Backed by its focus on operational excellence and sustainability, the company continues to expand in Indonesia,” added Riana Barnard, Best Practices Research Analyst.
Each year, Frost & Sullivan presents a Company of the Year Award to the organization that demonstrates excellence in terms of growth strategy and implementation in its field. The award recognizes a high degree of innovation with products and technologies, and the resulting leadership in terms of customer value and market penetration.
Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare industry participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the sector.
About Frost & SullivanFor six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.
Contact:Tarini SinghP: +91-9953764546E: [email protected]
About DCI Indonesia PT DCI Indonesia Tbk (DCI) is the first Tier IV data center in Southeast Asia that provides secure data center infrastructure services, guaranteeing a 99.999% SLA colocation or only five minutes of downtime per year. As a neutral data center operator, DCI is supported by 70+ network service providers. DCI Platform has 7 data centers in 3 locations: Cibitung, Karawang, and Jakarta with a total potential power capacity approaching 1,000 megawatts (MW).
With world-class operating standards, and equipped with state-of-the-art data center equipment, DCI provides maximum availability for customers to access their critical assets. This includes financial institutions, network service providers, e-commerce players, cloud service providers, and companies from other sectors. DCI has maintained a 100% uptime track record since its establishment. This performance stems from the proven experience of the leadership team in information technology, data center services, and infrastructure management, spanning over 25 years.
The demand for data centers in Indonesia continues to grow rapidly. DCI responds to this by committing to build sustainable data centers across its existing and new locations.
Contact:DCI MarketingE: [email protected]
Photo – https://mma.prnewswire.com/media/2453096/DCl_Indonesia_Award.jpg
View original content:https://www.prnewswire.co.uk/news-releases/dci-indonesia-awarded-by-frost–sullivan-for-world-class-operational-excellence-enabling-customers-to-grow-and-thrive-and-securing-a-market-leading-position-302188402.html
Artificial Intelligence
Grant Cardone Lists $42M Miami Mansion on Blockchain Real Estate Platform Propy
American best-selling author, businessman, and investor chooses Propy’s onchain real estate platform to list Golden Beach, Florida, house.
MIAMI, July 2, 2024 /PRNewswire/ — Propy, a technology company revolutionizing real estate via blockchain and AI, today announced that high-profile American entrepreneur Grant Cardone has listed a Golden Beach, Florida, private property for sale on Propy’s blockchain-based real estate platform with an asking price of $42,000,000 accepting cryptocurrency. This marks the first venture into emerging technologies in proptech for Cardone, a serial founder, best-selling author, equity fund manager, and business and real estate investor. The home is listed on the Propy marketplace with the deed minted onchain.
Propy simplifies the home-purchasing experience and eliminates fraudulent transactions by using a decentralized title registry and an escrow settlement protocol for securely storing land records and facilitating transactions, as well as accepting or converting cryptocurrency if a buyer chooses this form of payment. Leveraging the immutability of the blockchain, Propy ensures that buyer and seller private information is secure throughout the transaction. Automating and bringing the entire process online and onchain enables closing on a property to be faster, easier, and more secure than the outdated, traditional real estate transaction model.
Commenting on the listing, Grant Cardone said, “We are all in on blockchain revolutionizing real estate. We are leveraging top-tier technology to make transactions seamless and unstoppable. This is the future of real estate, and we’re leading the charge!”
The private address is minted on PropyKeys protocol – an onchain tokenized address market developed on the Base network (Coinbase Layer 2 on Ethereum). PropyKeys brings real estate onchain through NFT home addresses and aims to bring one million home addresses onchain by 2025. The Propy marketplace also grants prospective buyers the option to pay using Bitcoin or US dollars.
Natalia Karayaneva, Founder and CEO of Propy, said, “It is a privilege for us to be the platform of choice for high-end property sellers, enhancing our offering to our community of high net-worth individuals, investors, and crypto buyers. With Propy’s advanced blockchain rails, compliant crypto and dollar payments, and unwavering focus on privacy, our clients can confidently navigate the closing process. The inclusion of Cardone’s listing in BTC and USD on Propy, minted with our latest privacy deed feature, highlights our leadership in the intersection of real estate and crypto.”
Additional details on the Cardone property are available on Propy’s website. Interested parties should contact the listing agent for viewings and further details.
Natalia Karayaneva, Founder and CEO of Propy, is available for interview upon request.
About Propy:
Propy is a US-licensed title company and a pioneering platform leveraging blockchain and AI technology to facilitate seamless transactions of real-world assets (RWA), specifically focused on revolutionizing global real estate markets. As an industry leader, Propy specializes in providing secure and efficient solutions, ensuring an enhanced experience for buying and selling properties worldwide.
Website | Facebook | X
Photo: https://mma.prnewswire.com/media/2452961/Grant_Cardone_mansion.jpg
View original content:https://www.prnewswire.co.uk/news-releases/grant-cardone-lists-42m-miami-mansion-on-blockchain-real-estate-platform-propy-302188274.html
Artificial Intelligence
DataLend: Securities Lending Revenue Down 16% Year-Over-Year to $2.53 Billion in Q2 2024
Global revenue declines year-over-year due to lagging equities performance in the U.S. and EMEA
NEW YORK, July 2, 2024 /PRNewswire/ — The global securities finance industry generated $2.53 billion in revenue for lenders in the second quarter of 2024, according to DataLend, the market data service of fintech EquiLend. The figure represents a 16% decrease from the $3.00 billion generated in Q2 2023.
Global broker-to-broker activity, where broker-dealers lend and borrow securities from each other, generated an additional $696 million in revenue during Q2, a 9% decrease year-over-year.
Regionally, equity revenue fell 33% in EMEA and 19% in North America compared to the same period last year. A 22% decline in fees in North America and a 23% dip in EMEA accounted for the majority of the decreased revenue. Equity revenue in APAC increased 8% thanks to a 13% increase in fees.
Global fixed income performance declined by 11% in Q2 year-over-year. While revenue from government securities was roughly flat, corporate debt revenue fell by 32%, a regression of a trend which saw corporate bonds running hot through much of 2022 and 2023.
In June 2024, the global securities finance industry generated $790 million in revenue for lenders. The figure represents a 11% decrease year-over-year from the $888 million generated in June 2023. Broker-to-broker activity totaled an additional $207 million in revenue in June, also an 11% decrease year-over-year.
The top five earners in June 2024 were Lucid Group (LCID US), Trump Media & Technology Group (DJT US), Canopy Growth Corporation NPV (CGC US & WEED CN), Beyond Meat Inc. (BYND US) and ImmunityBio Inc. (IBRX US). In total, the group generated $56 million in revenue in the month.
Bloomberg Terminal users can subscribe to EquiLend’s exclusive Orbisa securities lending data by entering terminal shortcut APPS ORBISA or clicking the following link: https://blinks.bloomberg.com/screens/apps%20orbisa.
About DataLend
DataLend, the market data service within EquiLend’s Data & Analytics Solutions group, tracks daily market movements across more than 200,000 securities, covering $35 trillion in lendable assets and $2.6 trillion in on-loan assets for the securities finance market. www.datalend.com
About EquiLend
EquiLend is a global financial technology firm offering Trading, Post-Trade, Data & Analytics, RegTech and Platform Solutions for the securities finance industry. With offices in North America, EMEA and Asia-Pacific, EquiLend operates across various jurisdictions worldwide, adhering to the highest regulatory standards. The company is committed to excellence and innovation and is consistently recognized for its contributions to the industry. EquiLend is Great Place to Work Certified™ in the U.S., UK, Ireland and India and has been honored as the Best Post-Trade Service Provider Globally, Best Market Data Provider Globally and for its outstanding Diversity & Inclusion initiatives in the Securities Finance Times Industry Excellence Awards 2023. www.equilend.com
Logo – https://mma.prnewswire.com/media/1060364/EquiLend_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/datalend-securities-lending-revenue-down-16-year-over-year-to-2-53-billion-in-q2-2024–302188137.html
-
Artificial Intelligence5 days ago
CO2 AI Launches First Solution to Compute Product Emissions at Scale
-
Artificial Intelligence5 days agoSpotlight on Authentic AI: Developers Making Real Contributions Beyond AI Washing Claims
-
Artificial Intelligence4 days agoAsia Pacific View: Foreigners Looking for the Most Practical Smart Technology at the 2024 World Intelligence Expo
-
Artificial Intelligence4 days agoLucinity’s AI Innovation Recognized at Microsoft’s Prestigious Global Partner Awards 2024
-
Artificial Intelligence4 days ago
Tech Companies Leading the Charge in the Transformative AI Era
-
Artificial Intelligence5 days ago
Learning Pool Recognized with Two Industry Awards for Innovation and Product Excellence
-
Artificial Intelligence5 days agoHybrid Memory Cube Market Size to Grow USD 18651.2 Million by 2030 at a CAGR of 18.6% | Valuates Reports
-
Artificial Intelligence5 days ago
North American grocery retailer digitizes stores with Pricer Plaza in 90 MSEK order
